Molecule
Protein c concentrate human is a prescription medicine indicated for neonates, pediatric and adult patients with severe congenital Protein C deficiency for the prevention and treatment of venous thrombosis and purpura fulminans. MedsAcross supplies Protein c concentrate human for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
From the regulator-approved product information. Each section names its source.
CEPROTIN ®, Protein C Concentrate (Human), is an anticoagulant indicated for neonates, pediatric and adult patients with severe congenital Protein C deficiency for the prevention and treatment of venous thrombosis and purpura fulminans.
Source: US FDA prescribing information
Protein C is the precursor of a vitamin K-dependent anticoagulant glycoprotein (serine protease) that is synthesized in the liver. It is converted by the thrombin/thrombomodulin-complex on the endothelial cell surface to activated Protein C (APC). APC is a serine protease with potent anticoagulant effects, especially in the presence of its cofactor protein S. APC exerts its effect by the inactivation of the activated forms of factors V and VIII, which leads to a decrease in thrombin formation. APC has also been shown to have profibrinolytic effects. The Protein C pathway provides a natural mechanism for control of the coagulation system and prevention of excessive procoagulant responses to activating stimuli. A complete absence of protein C is not compatible with life.
Source: US FDA prescribing information
For intravenous administration only. Initiate treatment under the supervision of a physician experienced in using coagulation factors/inhibitors where monitoring of Protein C activity is feasible. Table provides the CEPROTIN dosing schedule for acute episodes, short-term prophylaxis, and long-term prophylaxis* Initial Dose Adjust the dose according to the pharmacokinetic profile for each individual patient. Subsequent 3 Doses Maintenance Dose *Dosing is based upon a clinical trial of 15 patients.
Source: US FDA prescribing information
None. None.
Source: US FDA prescribing information
Discontinue administration of CEPROTIN if symptoms of hypersensitivity/allergic reactions occur. Because CEPROTIN is made from human plasma, it may carry a risk of transmitting infectious agents, e.g., viruses, the variant Creutzfeldt-Jakob disease (vCJD) agent, and theoretically, the Creutzfeldt-Jakob disease agent. Simultaneous administration of CEPROTIN with tPA and/or anticoagulants may increase the risk of bleeding. CEPROTIN contains heparin. If heparin-induced thrombocytopenia is suspected, check platelet counts immediately and discontinue administration. CEPROTIN contains sodium >200 mg. Inform patients on a low sodium diet and/or patients with renal impairment.
Source: US FDA prescribing information
The common adverse reactions related to CEPROTIN treatment observed were the following hypersensitivity or allergic reactions: lightheadedness and itching and rash. Common adverse reactions observed in clinical trials were rash, itching, and lightheadedness.
Source: US FDA prescribing information
No formal drug interaction studies have been conducted. for information regarding simultaneous administration of CEPROTIN and tissue plasminogen activator (tPA).
Source: US FDA prescribing information
Store the vial in the original carton to protect it from light.
Source: US FDA prescribing information
For healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
1 presentations of Protein c concentrate human, sorted by availability.
| Medicine | Manufacturer | Register | Availability |
|---|---|---|---|
| Ceprotin kit | Takeda Pharmaceuticals | US FDA | Available on request |
1 brand names across 1 markets.
United States
Approval facts from US FDA, EMA and CDSCO data, and registration status by country where we hold register data.
| Register | Status | Source |
|---|---|---|
| US FDA | Not recorded | — |
| EU (EMA) | Not recorded | — |
| India (CDSCO) | Not yet confirmed against CDSCO approval lists | — |
| United States | Registered | US FDA (NDC directory, openFDA)Checked 12 November 2026 |
Yes, on request. MedsAcross lists 1 presentations of Protein c concentrate human and sources them for licensed hospitals, importers and physicians against valid import documents.
The catalogue lists 1 brand names for Protein c concentrate human, including Ceprotin.
No listed presentation of Protein c concentrate human is recorded as needing a cold chain. Storage conditions are shown on each presentation page.
Tell us the strength, quantity and destination country. Our team replies with availability, lead time and the import documents needed.